Literature DB >> 18332078

Comparison of immortalized Fa2N-4 cells and human hepatocytes as in vitro models for cytochrome P450 induction.

Niresh Hariparsad1, Brian A Carr, Raymond Evers, Xiaoyan Chu.   

Abstract

Fa2N-4 cells have been proposed as a tool to identify CYP3A4 inducers. To evaluate whether Fa2N-4 cells are a reliable surrogate for cryopreserved human hepatocytes, we assessed the basal mRNA expression of 64 drug disposition genes in Fa2N-4 cells. Significant differences were found in the expression of major drug-metabolizing enzymes, nuclear receptors, and transporters between both cell types. Importantly, the expression of constitutive androstane receptor (CAR) and several hepatic uptake transporters was significantly lower (>50-fold) in Fa2N-4 cells, whereas the expression of pregnane X-receptor (PXR) and aryl hydrocarbon receptor (AhR) was similar between Fa2N-4 cells and human hepatocytes. By using an optimized induction assay for Fa2N-4 cells, CYP3A4 induction by rifampicin, the prototypical PXR activator, increased from 1.5- to 7-fold at the level of functional activity. With nine selected compounds, which are known inducers of CYP3A4 either via activation of PXR, CAR, or both, we evaluated CYP3A4 and CYP2B6 mRNA induction using Fa2N-4 cells and human hepatocytes. No response was observed in Fa2N-4 cells treated with the selective CAR activators 6-(4-chlorophenyl)imidazo[2,1-b][1,3]-thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime and artemisinin. CYP3A4 and CYP2B6 induction in Fa2N-4 cells were also low for phenytoin, phenobarbital, and efavirenz, which are dual activators of PXR/CAR. This finding was in agreement with the lack of expression of CAR. The EC(50) value for rifampicin-mediated CYP3A4 induction was 10-fold higher than that in human hepatocytes. This result could be attributed to the low expression of hepatic organic anion-transporting polypeptides OATP1B1 and OATP1B3 in Fa2N-4 cells. In summary, our findings identify limitations of Fa2N-4 cells as a predictive induction model.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18332078     DOI: 10.1124/dmd.108.020677

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  20 in total

1.  Optimization of nonlinear dose- and concentration-response models utilizing evolutionary computation.

Authors:  Andrew L Beam; Alison A Motsinger-Reif
Journal:  Dose Response       Date:  2010-06-25       Impact factor: 2.658

2.  From the Cover: Three-Dimensional (3D) HepaRG Spheroid Model With Physiologically Relevant Xenobiotic Metabolism Competence and Hepatocyte Functionality for Liver Toxicity Screening.

Authors:  Sreenivasa C Ramaiahgari; Suramya Waidyanatha; Darlene Dixon; Michael J DeVito; Richard S Paules; Stephen S Ferguson
Journal:  Toxicol Sci       Date:  2017-09-01       Impact factor: 4.849

3.  Induction of CYP2C19 and CYP3A activity following repeated administration of efavirenz in healthy volunteers.

Authors:  V Michaud; E Ogburn; N Thong; A O Aregbe; T C Quigg; D A Flockhart; Z Desta
Journal:  Clin Pharmacol Ther       Date:  2012-02-08       Impact factor: 6.875

4.  Design, Synthesis, and Pharmacological Evaluation of Second Generation EZH2 Inhibitors with Long Residence Time.

Authors:  Avinash Khanna; Alexandre Côté; Shilpi Arora; Ludivine Moine; Victor S Gehling; Jehrod Brenneman; Nico Cantone; Jacob I Stuckey; Shruti Apte; Ashwin Ramakrishnan; Kamil Bruderek; William D Bradley; James E Audia; Richard T Cummings; Robert J Sims; Patrick Trojer; Julian R Levell
Journal:  ACS Med Chem Lett       Date:  2020-03-26       Impact factor: 4.345

5.  Impact of efavirenz on intestinal metabolism and transport: insights from an interaction study with ezetimibe in healthy volunteers.

Authors:  S Oswald; H E Meyer zu Schwabedissen; A Nassif; C Modess; Z Desta; E T Ogburn; J Mostertz; M Keiser; J Jia; A Hubeny; A Ulrich; D Runge; M Marinova; D Lütjohann; H K Kroemer; W Siegmund
Journal:  Clin Pharmacol Ther       Date:  2012-02-01       Impact factor: 6.875

6.  Fabrication of agarose concave petridish for 3D-culture microarray method for spheroids formation of hepatic cells.

Authors:  Binbin Zhang; Yang Li; Gaoshang Wang; Zhidong Jia; Haiyan Li; Qing Peng; Yi Gao
Journal:  J Mater Sci Mater Med       Date:  2018-04-19       Impact factor: 3.896

7.  Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).

Authors:  Faraz Kazmi; Tiffini Hensley; Chad Pope; Ryan S Funk; Greg J Loewen; David B Buckley; Andrew Parkinson
Journal:  Drug Metab Dispos       Date:  2013-02-01       Impact factor: 3.922

Review 8.  Predicting the clinical relevance of drug interactions from pre-approval studies.

Authors:  Silvio Caccia; Silvio Garattini; Luca Pasina; Alessandro Nobili
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

9.  Contextualizing Hepatocyte Functionality of Cryopreserved HepaRG Cell Cultures.

Authors:  Jonathan P Jackson; Linhou Li; Erica D Chamberlain; Hongbing Wang; Stephen S Ferguson
Journal:  Drug Metab Dispos       Date:  2016-06-23       Impact factor: 3.922

Review 10.  Organotypic liver culture models: meeting current challenges in toxicity testing.

Authors:  Edward L LeCluyse; Rafal P Witek; Melvin E Andersen; Mark J Powers
Journal:  Crit Rev Toxicol       Date:  2012-05-15       Impact factor: 5.635

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.